SCHEMBL2848669

SCHEMBL2848669

CC(C)(C)OC(=O)N(OC(C)(C)C)c1nccc2c(Br)c(N)ccc12

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.34
CSNK2A1 P68400 1/20 0.31
HIPK2 Q9H2X6 1/20 0.31
IMPDH2 P12268 1/20 0.31
AAK1 Q2M2I8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2848668 0.87 SSTR4 (0.36) SSTR4CSNK2A1HIPK2IMPDH2AAK1
SCHEMBL5003279 0.86 SSTR4 (0.36) SSTR4
SCHEMBL2857004 0.78 NR1H4 (0.33) SSTR4CSNK2A1HIPK2
SCHEMBL6919158 0.73 PDPK1 (0.34) SSTR4
SCHEMBL6918452 0.72 PDPK1 (0.34) SSTR4IMPDH2AAK1
SCHEMBL5003275 0.72 SSTR4 (0.38) SSTR4
SCHEMBL15821659 0.72 PDPK1 (0.34) SSTR4
SCHEMBL13513327 0.72 PDPK1 (0.34) SSTR4
SCHEMBL2855164 0.72 LMNA (0.35)
SCHEMBL15820601 0.71 PDPK1 (0.33) SSTR4AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910298-B1 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS BRISTOL MYERS SQUIBB CO (US) 2010-01-13 EP disclosed
US-7456195-B2 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-25 US disclosed
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants F12, F11, F7 SSTR4 2840/4885CSNK2A1 903/4885HIPK2 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.